(Q45870525)

17 December 2017

title

Combining gene and immunotherapy for prostate cancer (English)

1 reference

17 December 2017

1 reference

Young JG

1

1 reference

17 December 2017

Green NK

2

1 reference

17 December 2017

Mautner V

3

1 reference

17 December 2017

Searle PF

4

1 reference

17 December 2017

Young LS

5

1 reference

17 December 2017

James ND

6

1 reference

17 December 2017

publication date

28 August 2007

1 reference

17 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

17 December 2017

volume

11

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

187-193

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4501008

exact match

0 references

cites work

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Phase II trial of GM-CSF in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Stress proteins and the immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Natural adjuvants: endogenous activators of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Danger signals: SOS to the immune system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501008

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4501008

1 reference

17 December 2017

Dimensions Publication ID

1019806200

0 references

1 reference

17 December 2017